Biophytis

Romainville, France Founded: 2006 • Age: 20 yrs
Drugs for neuromuscular and age-related diseases are developed.

About Biophytis

Biophytis is a company based in Romainville (France) founded in 2006.. Biophytis has raised $2.6 million across 5 funding rounds from investors including Seventure Partners and CM-CIC Capital Prive. The company has 20 employees as of December 31, 2024. Biophytis offers products and services including BIO101 and Macuneos (BIO201). Biophytis operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Biological E, Vir Biotechnology and Neurocrine, among others.

  • Headquarter Romainville, France
  • Employees 20 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Biophytis Sa
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $0 (USD)
    0
    as on Dec 31, 2024
  • Net Profit
    $-10.78 M (USD)
    39.04
    as on Dec 31, 2024
  • EBITDA
    $-9.71 M (USD)
    38.02
    as on Dec 31, 2024
  • Total Equity Funding
    $2.6 M (USD)

    in 5 rounds

  • Latest Funding Round
    $38.22 M (USD), Post-IPO

    Jun 18, 2021

  • Investors
  • Employee Count
    20

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Biophytis

Biophytis is a publicly listed company on the EURONEXT with ticker symbol ALBPS in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: EURONEXT · Ticker: ALBPS . Sector: Health technology · France

Products & Services of Biophytis

Biophytis offers a comprehensive portfolio of products and services, including BIO101 and Macuneos (BIO201). The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Oral molecule for treating sarcopenia and neuromuscular conditions.

Oral treatment for retinal diseases like macular degeneration.

People of Biophytis
Headcount 10-50
Employee Profiles 6
Board Members and Advisors 8
Employee Profiles
People
Pierre J. Dilda
Chief Scientific Officer
People
Stanislas Veillet
Chairman & CEO
People
Rob Van Maanen
Chief Medical Officer
People
Cendrine Tourette
Translational and clinical research project leader in neuromuscular diseases

Unlock access to complete

Board Members and Advisors
people
José-Alain Sahel
Scientific Advisor
people
René Lafont
Scientific Advisor
people
Ivana Kim
Scientific Advisor
people
Nadine Coulm
Director

Unlock access to complete

Funding Insights of Biophytis

Biophytis has successfully raised a total of $2.6M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $38.22 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Post-IPO — $38.2M
  • First Round

    (01 Oct 2012)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2021 Amount Post-IPO - Biophytis Valuation

investors

Jul, 2020 Amount Post-IPO - Biophytis Valuation

investors

Oct, 2017 Amount Post-IPO - Biophytis Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Biophytis

Biophytis has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Seventure Partners and CM-CIC Capital Prive. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US
Founded Year Domain Location
Private equity firm focused on SMEs
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Biophytis

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Biophytis

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Biophytis Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Biophytis

Biophytis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Biological E, Vir Biotechnology and Neurocrine, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Therapies for neurodegenerative and immunology disorders are developed.
domain founded_year HQ Location
Vaccines and therapeutics for multiple diseases are developed and marketed.
domain founded_year HQ Location
Developer of therapeutics for the treatment of infectious diseases
domain founded_year HQ Location
Developer of small molecule therapeutics for endocrine and CNS disorders
domain founded_year HQ Location
Small molecule drugs for rare diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Biophytis

Frequently Asked Questions about Biophytis

When was Biophytis founded?

Biophytis was founded in 2006 and raised its 1st funding round 6 years after it was founded.

Where is Biophytis located?

Biophytis is headquartered in Romainville, France. It is registered at Romainville, Ile-de-france, France.

Is Biophytis a funded company?

Biophytis is a funded company, having raised a total of $2.6M across 5 funding rounds to date. The company's 1st funding round was a Post-IPO of $12.26M, raised on Oct 01, 2012.

How many employees does Biophytis have?

As of Dec 31, 2024, the latest employee count at Biophytis is 20.

What does Biophytis do?

The company was founded in 2006 and is headquartered in Romainville, France. Focus is placed on the biotechnology sector, where treatments for neuromuscular and age-related conditions are developed. Sarconeos (BIO101), an oral small molecule, is advanced for sarcopenia and Duchenne muscular dystrophy. Macuneos (BIO201) is pursued for retinal disorders such as dry age-related macular degeneration and Stargardt disease. Operations center on clinical-stage drug candidates.

Who are the top competitors of Biophytis?

Biophytis's top competitors include Jazz Pharmaceuticals, Vaxcyte and PTC Therapeutics.

What products or services does Biophytis offer?

Biophytis offers BIO101 and Macuneos (BIO201).

Is Biophytis publicly traded?

Yes, Biophytis is publicly traded on EURONEXT under the ticker symbol ALBPS.

Who are Biophytis's investors?

Biophytis has 2 investors. Key investors include Seventure Partners, and CM-CIC Capital Prive.

What is Biophytis's ticker symbol?

The ticker symbol of Biophytis is ALBPS on EURONEXT.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available